We identify determinants of plasma interleukin-6 (IL-6) levels in a multicenter panel study of myocardial infarction (Ml) survivors, using repeated measurements to evaluate both baseline and time-varying factors.
Design and methods
Survivors of Ml (N=1003) recruited in six European cities had repeated measurements (median: 6/patient) of IL-6. At baseline, participants’ behaviour and medical histories were determined by interview, and blood pressure, anthropometry, cholesterol and N-terminal B-type natriuretic peptide (NT-proBNP) were measured. Short-term exposures and medication intake were recorded at each visit. Generalized additive mixed models were used to analyze associations of IL-6 with baseline and time-varying risk factors, taking into account repeated measurements.
Results
Age, hour of blood withdrawal, body mass index, pack-years of smoking, NT-proBNP, systolic blood pressure, high-density lipoprotein cholesterol, persistent cough/phlegm and statin use were significantly and independently associated with IL-6 after adjustment for city, recurrent Ml, baseline alcohol intake, current active smoking, tea consumption and extreme anger or stress.
BermudezEARifaiNBuringJMansonJERidkerPM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol2002; 22:1668–1673.
2.
WoodsABrullDJHumphriesSEMontgomeryHE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J2000; 21:1574–1583.
3.
Von der ThusenJHKuiperJvan BerkelTJBiessenEA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev2003; 55:133–166.
4.
CesariMPenninxBWNewmanABKritchevskySBNicklasBJSutton-TyrrellKInflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation2003; 108:2317–2322.
5.
PaiJKPischonTMaJMansonJAEHankinsonSEJoshipuraKInflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med2004; 351:2599–2610.
6.
RidkerPMRifaiNStampferMJHennekensCH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation2000; 101:1767–1772.
7.
BozkurtB. Activation of cytokines as a mechanism of disease progression in heart failureAnn Rheum Dis2000; 59 (Suppl I):i90–i93.
8.
HartfordMWiklundOMattsson HultenLPerersEPersonAHerlitzJCRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol2006; 108:55–62.
9.
MeredithITPlunkettJCWorthleySGHopeSACameronJD. Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering. Coron Artery Dis2005; 16:415–422.
10.
ZiakasAGavrilidisSGiannoglouGSouliouEGemitzisKKalampalikaDIn-hospital and long-term prognostic value of fibrinogen, CRP, and IL-6 levels in patients with acute myocardial infarction treated with thrombolysis. Angiology2006; 57:283–293.
11.
TracyRP. Inflammation in cardiovascular disease: cart, horse, or both-revisited. (Editorial) Arterioscler Thromb Vasc Biol2002; 22:1514–1515.
12.
BogatyPBrophyJMBoyerLSimardSJosephLBertrandFFluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med2005; 165:221–226.
13.
CavaFGonzalezCPascualMJNavajoJAGonzalez-BuitragoJM. Biological variation of interleukin 6 (IL-6) and soluble interleukin 2 receptor (slL2R) in serum of healthy individuals. Cytokine2000; 12:1423–1425.
14.
PetersASchneiderAGrevenSBellanderTForastiereFIbald-MulliA; for The AIRGENE Study Group. Air pollution and inflammatory response in myocardial infarction survivors: gene-environment-interactions in a high-risk group. Study design of The AIRGENE StudyInhal Toxicol2007; 19 (Suppl 1):161–175.
15.
GrevenSKüchenhoffHPetersA. Additive mixed models with P-Splines. Proceedings of the 21st International Workshop on Statistical Modelling (2006), 201–207.
16.
ChanJCCheungJCStehouwerCDEmeisJJTongPCKoGTThe central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome-an analysis by structural equation modelling. Int J Obes Relat Metab Disord2002; 26:994–1008.
17.
MarzWWinklerKNauckMBohmBOWinkelmannBR. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol2003; 92:305–308.
18.
VgontzasANBixlerEOLinHMProloPTrakadaGChrousosGP. IL-6 and its circadian secretion in humans. Neuroimmunomodulation2005; 12:131–140.
19.
MendallMAPatelPAsanteMBallamLMorrisJStrachanDPRelation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart1997; 78:273–277.
20.
WrightCBSaccoRLRundekTRDelmanJBRabbaniLEElkindMSV. Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. J Stroke Cerebrovasc Dis2006; 15:34–38.
21.
WannametheeSGWhincupPHRumleyALoweGD. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost2007; 5:1637–1643.
22.
KosterABosmaHPenninxBWNewmanABHarrisTBvan EijkJT; Health ABC Study. Association of inflammatory markers with socioeconomic status. J Gerontol A Biol Sci Med Sci2006; 61:284–290.
PicheMELemieuxSWeisnagelSJCorneauLNadeauABergeronJ. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol2005; 96:92–97.
25.
WaltherCMöbius-WinklerSLinkeABruegelMThieryJSchulerGRegular exercise training compared with percutaneous intervention leads to a reduction of inflammatory markers and cardiovascular events in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil2008; 15:107–112.
26.
Panagiotakos DB, Pitsavos C, Chrysohoou C, Kavouras S, Stefanadis C; ATTICA Study.The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA Study. Prev Med2005; 40:432–437.
27.
HelmerssonJLarssonAVessbyBBasuS. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis2005; 181:201–207.
28.
VolpatoSFellinR. [Alcohol consumption and circulating markers of inflammation]. Recenti Prog Med2005; 96:102–107.
29.
WilliamsMJSutherlandWHWhelanAPMcCormickMPde JongSA. Acute effect of drinking red and white wines on circulating levels of inflammation-sensitive molecules in men with coronary artery disease. Metabolism2004; 53:318–323.
30.
DanielssonPTruedssonLErikssonK-FNorgrenL. Inflammatory markers and IL-6 polymorphism is peripheral arterial disease with and without diabetes mellitus. Vasc Med2005; 10:191–198.
31.
EmdinMPassinoCPronteraCIervasiARipoliAMasiniSCardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med2004; 42:627–636.
32.
YasudaNGotohKMinatoguchiSAsanoKNishigakiKNomuraMAn increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med1998; 92:993–999.
